Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2014

Open Access 01-12-2014 | Review

The multiple facets of drug resistance: one history, different approaches

Authors: Evandro Luís Niero, Bianca Rocha-Sales, Camila Lauand, Beatriz Araujo Cortez, Marcelo Medina de Souza, Paula Rezende-Teixeira, Marcel Shiniti Urabayashi, Adam Arai Martens, Jorge Henrique Neves, Gláucia Maria Machado-Santelli

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2014

Login to get access

Abstract

Some cancers like melanoma and pancreatic and ovarian cancers, for example, commonly display resistance to chemotherapy, and this is the major obstacle to a better prognosis of patients. Frequently, literature presents studies in monolayer cell cultures, 3D cell cultures or in vivo studies, but rarely the same work compares results of drug resistance in different models. Several of these works are presented in this review and show that usually cells in 3D culture are more resistant to drugs than monolayer cultured cells due to different mechanisms. Searching for new strategies to sensitize different tumors to chemotherapy, many methods have been studied to understand the mechanisms whereby cancer cells acquire drug resistance. These methods have been strongly advanced along the years and therapies using different drugs have been increasingly proposed to induce cell death in resistant cells of different cancers. Recently, cancer stem cells (CSCs) have been extensively studied because they would be the only cells capable of sustaining tumorigenesis. It is believed that the resistance of CSCs to currently used chemotherapeutics is a major contributing factor in cancer recurrence and later metastasis development. This review aims to appraise the experimental progress in the study of acquired drug resistance of cancer cells in different models as well as to understand the role of CSCs as the major contributing factor in cancer recurrence and metastasis development, describing how CSCs can be identified and isolated.
Appendix
Available only for authorised users
Literature
1.
go back to reference Christakis P: The birth of chemotherapy at Yale. Bicentennial lecture series: Surgery Grand Round. Yale J Biol Med. 2011, 84: 169-172.PubMedCentralPubMed Christakis P: The birth of chemotherapy at Yale. Bicentennial lecture series: Surgery Grand Round. Yale J Biol Med. 2011, 84: 169-172.PubMedCentralPubMed
2.
go back to reference Miller DR: A tribute to Sidney Farber– the father of modern chemotherapy. Br J Haematol. 2006, 134: 20-26. 10.1111/j.1365-2141.2006.06119.x.PubMedCrossRef Miller DR: A tribute to Sidney Farber– the father of modern chemotherapy. Br J Haematol. 2006, 134: 20-26. 10.1111/j.1365-2141.2006.06119.x.PubMedCrossRef
3.
go back to reference Frei E, Freireich E, Gehan E: Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Blood. 1961, 18: 431-454. Frei E, Freireich E, Gehan E: Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Blood. 1961, 18: 431-454.
4.
go back to reference Freireich E, Gehan E: The effect of 6-mercaptopurine on the duration of steroid-induced remissions in acute leukemia: a model for evaluation of other potentially useful therapy. Blood. 1963, 21: 699-716. Freireich E, Gehan E: The effect of 6-mercaptopurine on the duration of steroid-induced remissions in acute leukemia: a model for evaluation of other potentially useful therapy. Blood. 1963, 21: 699-716.
5.
go back to reference Frei E, Karon M, Levin RH, Freireich EJ, Taylor RJ, Hananian J, Selawry O, Holland JF, Hoogstraten B, Wolman IJ, Abir E, Sawitsky A, Lee S, Mills SD, Burgert EO, Spurr CL, Patterson RB, Ebaugh FG, James GW, Moon JH: The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood. 1965, 26: 642-656.PubMed Frei E, Karon M, Levin RH, Freireich EJ, Taylor RJ, Hananian J, Selawry O, Holland JF, Hoogstraten B, Wolman IJ, Abir E, Sawitsky A, Lee S, Mills SD, Burgert EO, Spurr CL, Patterson RB, Ebaugh FG, James GW, Moon JH: The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood. 1965, 26: 642-656.PubMed
6.
go back to reference DeVita VT, Chu E: A history of cancer chemotherapy. Cancer Res. 2008, 68: 8643-8653. 10.1158/0008-5472.CAN-07-6611.PubMedCrossRef DeVita VT, Chu E: A history of cancer chemotherapy. Cancer Res. 2008, 68: 8643-8653. 10.1158/0008-5472.CAN-07-6611.PubMedCrossRef
7.
go back to reference LAW LW: Origin of the resistance of leukaemic cells to folic acid antagonists. Nature. 1952, 169: 628-629. 10.1038/169628a0.PubMedCrossRef LAW LW: Origin of the resistance of leukaemic cells to folic acid antagonists. Nature. 1952, 169: 628-629. 10.1038/169628a0.PubMedCrossRef
8.
9.
go back to reference Chen Y, Liu H, Wu W, Li Y, Li J: Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res. 2013, 32: 45-10.1186/1756-9966-32-45.PubMedCentralPubMedCrossRef Chen Y, Liu H, Wu W, Li Y, Li J: Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res. 2013, 32: 45-10.1186/1756-9966-32-45.PubMedCentralPubMedCrossRef
10.
go back to reference Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X: TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 2012, 31: 6-10.1186/1756-9966-31-6.PubMedCentralPubMedCrossRef Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X: TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 2012, 31: 6-10.1186/1756-9966-31-6.PubMedCentralPubMedCrossRef
11.
go back to reference Wang G, Zhang J, Liu L, Sharma S, Dong Q: Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One. 2012, 7: e51764-10.1371/journal.pone.0051764.PubMedCentralPubMedCrossRef Wang G, Zhang J, Liu L, Sharma S, Dong Q: Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS One. 2012, 7: e51764-10.1371/journal.pone.0051764.PubMedCentralPubMedCrossRef
12.
go back to reference Goldenberg GJ, Begleiter A: Membrane transport of alkylating agents. Pharmacol Ther. 1980, 8: 237-274. 10.1016/0163-7258(80)90048-0.PubMedCrossRef Goldenberg GJ, Begleiter A: Membrane transport of alkylating agents. Pharmacol Ther. 1980, 8: 237-274. 10.1016/0163-7258(80)90048-0.PubMedCrossRef
13.
go back to reference Fry DW, Jackson RC: Membrane transport alterations as a mechanism of resistance to anticancer agents. Cancer Surv. 1986, 5: 47-79.PubMed Fry DW, Jackson RC: Membrane transport alterations as a mechanism of resistance to anticancer agents. Cancer Surv. 1986, 5: 47-79.PubMed
14.
go back to reference Kessel D, Botterill V, Wodinsky I: Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Res. 1968, 28: 938-941.PubMed Kessel D, Botterill V, Wodinsky I: Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Res. 1968, 28: 938-941.PubMed
15.
go back to reference Nowell PC: The clonal evolution of tumor cell populations. Science. 1976, 194: 23-28. 10.1126/science.959840.PubMedCrossRef Nowell PC: The clonal evolution of tumor cell populations. Science. 1976, 194: 23-28. 10.1126/science.959840.PubMedCrossRef
16.
go back to reference Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994, 367: 645-648. 10.1038/367645a0.PubMedCrossRef Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994, 367: 645-648. 10.1038/367645a0.PubMedCrossRef
17.
go back to reference Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997, 3: 730-737. 10.1038/nm0797-730.PubMedCrossRef Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997, 3: 730-737. 10.1038/nm0797-730.PubMedCrossRef
18.
go back to reference Visvader JE, Lindeman GJ: Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012, 10: 717-728. 10.1016/j.stem.2012.05.007.PubMedCrossRef Visvader JE, Lindeman GJ: Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012, 10: 717-728. 10.1016/j.stem.2012.05.007.PubMedCrossRef
19.
go back to reference Bai J, Sui J, Demirjian A, Vollmer CM, Marasco W, Callery MP: Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005, 65: 2344-2352. 10.1158/0008-5472.CAN-04-3502.PubMedCrossRef Bai J, Sui J, Demirjian A, Vollmer CM, Marasco W, Callery MP: Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005, 65: 2344-2352. 10.1158/0008-5472.CAN-04-3502.PubMedCrossRef
20.
go back to reference Wang W, Cassidy J: Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br J Cancer. 2003, 88: 624-629. 10.1038/sj.bjc.6600753.PubMedCentralPubMedCrossRef Wang W, Cassidy J: Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br J Cancer. 2003, 88: 624-629. 10.1038/sj.bjc.6600753.PubMedCentralPubMedCrossRef
21.
go back to reference Wang W, McLeod HL, Cassidy J: Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer. 2003, 104: 504-511. 10.1002/ijc.10972.PubMedCrossRef Wang W, McLeod HL, Cassidy J: Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer. 2003, 104: 504-511. 10.1002/ijc.10972.PubMedCrossRef
22.
go back to reference Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M: MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int. 2013, 2013: 241763-PubMedCentralPubMedCrossRef Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M: MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int. 2013, 2013: 241763-PubMedCentralPubMedCrossRef
23.
go back to reference Krishan A, Fitz CM, Andritsch I: Drug retention, efflux, and resistance in tumor cells. Cytometry. 1997, 29: 279-285. 10.1002/(SICI)1097-0320(19971201)29:4<279::AID-CYTO3>3.0.CO;2-5.PubMedCrossRef Krishan A, Fitz CM, Andritsch I: Drug retention, efflux, and resistance in tumor cells. Cytometry. 1997, 29: 279-285. 10.1002/(SICI)1097-0320(19971201)29:4<279::AID-CYTO3>3.0.CO;2-5.PubMedCrossRef
24.
go back to reference Aran JM, Gottesman MM, Pastan I: Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Proc Natl Acad Sci U S A. 1994, 91: 3176-3180. 10.1073/pnas.91.8.3176.PubMedCentralPubMedCrossRef Aran JM, Gottesman MM, Pastan I: Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Proc Natl Acad Sci U S A. 1994, 91: 3176-3180. 10.1073/pnas.91.8.3176.PubMedCentralPubMedCrossRef
25.
go back to reference Munoz M, Henderson M, Haber M, Norris M: Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 2007, 59: 752-757. 10.1080/15216540701736285.PubMedCrossRef Munoz M, Henderson M, Haber M, Norris M: Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 2007, 59: 752-757. 10.1080/15216540701736285.PubMedCrossRef
26.
27.
go back to reference Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987, 84: 7735-7738. 10.1073/pnas.84.21.7735.PubMedCentralPubMedCrossRef Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987, 84: 7735-7738. 10.1073/pnas.84.21.7735.PubMedCentralPubMedCrossRef
28.
go back to reference Jelly ND, Hussain II, Eremin J, Eremin O, El-Sheemy M: The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells. Cancer Cell Int. 2012, 12: 21-10.1186/1475-2867-12-21.PubMedCentralPubMedCrossRef Jelly ND, Hussain II, Eremin J, Eremin O, El-Sheemy M: The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells. Cancer Cell Int. 2012, 12: 21-10.1186/1475-2867-12-21.PubMedCentralPubMedCrossRef
29.
go back to reference Kalalinia F, Elahian F, Hassani M, Kasaeeian J, Behravan J: Phorbol ester TPA modulates chemoresistance in the drug sensitive breast cancer cell line MCF-7 by inducing expression of drug efflux transporter ABCG2. Asian Pac J Cancer Prev. 2012, 13: 2979-2984. 10.7314/APJCP.2012.13.6.2979.PubMedCrossRef Kalalinia F, Elahian F, Hassani M, Kasaeeian J, Behravan J: Phorbol ester TPA modulates chemoresistance in the drug sensitive breast cancer cell line MCF-7 by inducing expression of drug efflux transporter ABCG2. Asian Pac J Cancer Prev. 2012, 13: 2979-2984. 10.7314/APJCP.2012.13.6.2979.PubMedCrossRef
30.
go back to reference Ferreira PA, Ruela-de-Sousa RR, Queiroz KCS, Souza ACS, Milani R, Pilli RA, Peppelenbosch MP, den Hertog J, Ferreira CV: Knocking down low molecular weight protein tyrosine phosphatase (LMW-PTP) reverts chemoresistance through inactivation of Src and Bcr-Abl proteins. PLoS One. 2012, 7: e44312-10.1371/journal.pone.0044312.PubMedCentralPubMedCrossRef Ferreira PA, Ruela-de-Sousa RR, Queiroz KCS, Souza ACS, Milani R, Pilli RA, Peppelenbosch MP, den Hertog J, Ferreira CV: Knocking down low molecular weight protein tyrosine phosphatase (LMW-PTP) reverts chemoresistance through inactivation of Src and Bcr-Abl proteins. PLoS One. 2012, 7: e44312-10.1371/journal.pone.0044312.PubMedCentralPubMedCrossRef
31.
go back to reference Van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovée JVMG: Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol. 2012, 23: 1617-1626. 10.1093/annonc/mdr512.PubMedCrossRef Van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovée JVMG: Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol. 2012, 23: 1617-1626. 10.1093/annonc/mdr512.PubMedCrossRef
32.
go back to reference Sui H, Fan Z-Z, Li Q: Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 2012, 40: 426-435. 10.1177/147323001204000204.PubMedCrossRef Sui H, Fan Z-Z, Li Q: Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 2012, 40: 426-435. 10.1177/147323001204000204.PubMedCrossRef
33.
go back to reference Zöchbauer-Müller S, Filipits M, Rudas M, Brunner R, Krajnik G, Suchomel R, Schmid K, Pirker R: P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients. Anticancer Res. 2001, 21: 119-124.PubMed Zöchbauer-Müller S, Filipits M, Rudas M, Brunner R, Krajnik G, Suchomel R, Schmid K, Pirker R: P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients. Anticancer Res. 2001, 21: 119-124.PubMed
34.
go back to reference dit Faute MA, Laurent L, Ploton D, Poupon M-F, Jardillier J-C, Bobichon H: Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis. 2002, 19: 161-168. 10.1023/A:1014594825502.PubMedCrossRef dit Faute MA, Laurent L, Ploton D, Poupon M-F, Jardillier J-C, Bobichon H: Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis. 2002, 19: 161-168. 10.1023/A:1014594825502.PubMedCrossRef
35.
go back to reference Shi Y, Liu C, Liu X, Tang DG, Wang J: The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One. 2014, 9: e90022-10.1371/journal.pone.0090022.PubMedCentralPubMedCrossRef Shi Y, Liu C, Liu X, Tang DG, Wang J: The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One. 2014, 9: e90022-10.1371/journal.pone.0090022.PubMedCentralPubMedCrossRef
36.
37.
go back to reference Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y, Wang Y, Chen Q, Zhao X, Zhou M, Cui Z, Zheng Z, Wang E, Wei M: MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat. 2013, 139: 717-730. 10.1007/s10549-013-2607-x.PubMedCrossRef Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y, Wang Y, Chen Q, Zhao X, Zhou M, Cui Z, Zheng Z, Wang E, Wei M: MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat. 2013, 139: 717-730. 10.1007/s10549-013-2607-x.PubMedCrossRef
38.
go back to reference Skulachev VP: Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett. 1998, 423: 275-280. 10.1016/S0014-5793(98)00061-1.PubMedCrossRef Skulachev VP: Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett. 1998, 423: 275-280. 10.1016/S0014-5793(98)00061-1.PubMedCrossRef
39.
go back to reference Fichtinger-Schepman AM, van Oosterom AT, Lohman PH, Berends F: cis-Diamminedichloroplatinum (II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum (II). Cancer Res. 1987, 47: 3000-3004.PubMed Fichtinger-Schepman AM, van Oosterom AT, Lohman PH, Berends F: cis-Diamminedichloroplatinum (II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum (II). Cancer Res. 1987, 47: 3000-3004.PubMed
40.
go back to reference Reed E, Litterst CL, Thill CC, Yuspa SH, Poirier MC: cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats. Cancer Res. 1987, 47: 718-722.PubMed Reed E, Litterst CL, Thill CC, Yuspa SH, Poirier MC: cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats. Cancer Res. 1987, 47: 718-722.PubMed
42.
go back to reference De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J: Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci U S A. 1981, 78: 5608-5612. 10.1073/pnas.78.9.5608.PubMedCentralPubMedCrossRef De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J: Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci U S A. 1981, 78: 5608-5612. 10.1073/pnas.78.9.5608.PubMedCentralPubMedCrossRef
43.
go back to reference Long BH, Fairchild CR: Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. Cancer Res. 1994, 54: 4355-4361.PubMed Long BH, Fairchild CR: Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. Cancer Res. 1994, 54: 4355-4361.PubMed
44.
go back to reference Wallace-Brodeur RR, Lowe SW: Clinical implications of p53 mutations. Cell Mol Life Sci. 1999, 55: 64-75. 10.1007/s000180050270.PubMedCrossRef Wallace-Brodeur RR, Lowe SW: Clinical implications of p53 mutations. Cell Mol Life Sci. 1999, 55: 64-75. 10.1007/s000180050270.PubMedCrossRef
45.
go back to reference Satyamoorthy K, Bogenrieder T, Herlyn M: No longer a molecular black box–new clues to apoptosis and drug resistance in melanoma. Trends Mol Med. 2001, 7: 191-194. 10.1016/S1471-4914(01)02013-5.PubMedCrossRef Satyamoorthy K, Bogenrieder T, Herlyn M: No longer a molecular black box–new clues to apoptosis and drug resistance in melanoma. Trends Mol Med. 2001, 7: 191-194. 10.1016/S1471-4914(01)02013-5.PubMedCrossRef
46.
go back to reference Karin M, Cao Y, Greten FR, Li Z-W: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2: 301-310. 10.1038/nrc780.PubMedCrossRef Karin M, Cao Y, Greten FR, Li Z-W: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2: 301-310. 10.1038/nrc780.PubMedCrossRef
47.
go back to reference Lee DH, Macintyre JP, Taylor GR, Wang E, Plante RK, Tam SS, Pope BL, Lau CY: Tepoxalin enhances the activity of an antioxidant, pyrrolidine dithiocarbamate, in attenuating tumor necrosis factor alpha-induced apoptosis in WEHI 164 cells. J Pharmacol Exp Ther. 1999, 289: 1465-1471.PubMed Lee DH, Macintyre JP, Taylor GR, Wang E, Plante RK, Tam SS, Pope BL, Lau CY: Tepoxalin enhances the activity of an antioxidant, pyrrolidine dithiocarbamate, in attenuating tumor necrosis factor alpha-induced apoptosis in WEHI 164 cells. J Pharmacol Exp Ther. 1999, 289: 1465-1471.PubMed
48.
go back to reference Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999, 18: 6853-6866. 10.1038/sj.onc.1203239.PubMedCrossRef Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999, 18: 6853-6866. 10.1038/sj.onc.1203239.PubMedCrossRef
49.
go back to reference Voboril R, Hochwald SN, Li J, Brank A, Weberova J, Wessels F, Moldawer LL, Camp ER, MacKay SLD: Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J Surg Res. 2004, 120: 178-188. 10.1016/j.jss.2003.11.023.PubMedCrossRef Voboril R, Hochwald SN, Li J, Brank A, Weberova J, Wessels F, Moldawer LL, Camp ER, MacKay SLD: Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J Surg Res. 2004, 120: 178-188. 10.1016/j.jss.2003.11.023.PubMedCrossRef
50.
go back to reference El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH: Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 2006, 66: 10553-10559. 10.1158/0008-5472.CAN-06-2333.PubMedCrossRef El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH: Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 2006, 66: 10553-10559. 10.1158/0008-5472.CAN-06-2333.PubMedCrossRef
51.
go back to reference Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse M, Fölsch UR, Schäfer H: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003, 22: 3243-3251. 10.1038/sj.onc.1206390.PubMedCrossRef Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse M, Fölsch UR, Schäfer H: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003, 22: 3243-3251. 10.1038/sj.onc.1206390.PubMedCrossRef
52.
go back to reference Banerjee S, Wang Z, Kong D, Sarkar FH: 3,3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 2009, 69: 5592-5600. 10.1158/0008-5472.CAN-09-0838.PubMedCentralPubMedCrossRef Banerjee S, Wang Z, Kong D, Sarkar FH: 3,3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 2009, 69: 5592-5600. 10.1158/0008-5472.CAN-09-0838.PubMedCentralPubMedCrossRef
53.
go back to reference Müerköster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Fölsch UR, Schäfer H: Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer. 2003, 104: 469-476. 10.1002/ijc.10963.PubMedCrossRef Müerköster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Fölsch UR, Schäfer H: Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer. 2003, 104: 469-476. 10.1002/ijc.10963.PubMedCrossRef
54.
go back to reference Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M: Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets. 2011, 15: 817-828. 10.1517/14728222.2011.566216.PubMedCentralPubMedCrossRef Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M: Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets. 2011, 15: 817-828. 10.1517/14728222.2011.566216.PubMedCentralPubMedCrossRef
55.
go back to reference Wang Y-W, Wang S-J, Zhou Y-N, Pan S-H, Sun B: Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol. 2012, 138: 785-797. 10.1007/s00432-012-1152-z.PubMedCrossRef Wang Y-W, Wang S-J, Zhou Y-N, Pan S-H, Sun B: Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol. 2012, 138: 785-797. 10.1007/s00432-012-1152-z.PubMedCrossRef
56.
go back to reference Xiao G, Wei J: Effects of beta-Aescin on the expression of nuclear factor-kappaB and tumor necrosis factor-alpha after traumatic brain injury in rats. J Zhejiang Univ Sci B. 2005, 6: 28-32.PubMedCentralPubMedCrossRef Xiao G, Wei J: Effects of beta-Aescin on the expression of nuclear factor-kappaB and tumor necrosis factor-alpha after traumatic brain injury in rats. J Zhejiang Univ Sci B. 2005, 6: 28-32.PubMedCentralPubMedCrossRef
57.
go back to reference Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, Aggarwal BB: Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol. 2010, 77: 818-827. 10.1124/mol.109.062760.PubMedCentralPubMedCrossRef Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, Aggarwal BB: Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol. 2010, 77: 818-827. 10.1124/mol.109.062760.PubMedCentralPubMedCrossRef
58.
go back to reference Patlolla JMR, Raju J, Swamy MV, Rao CV: Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21(waf1/cip1) in colon cancer cells. Mol Cancer Ther. 2006, 5: 1459-1466. 10.1158/1535-7163.MCT-05-0495.PubMedCrossRef Patlolla JMR, Raju J, Swamy MV, Rao CV: Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21(waf1/cip1) in colon cancer cells. Mol Cancer Ther. 2006, 5: 1459-1466. 10.1158/1535-7163.MCT-05-0495.PubMedCrossRef
59.
go back to reference Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G: Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2010, 334: 285-293. 10.1124/jpet.110.165498.PubMedCrossRef Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G: Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2010, 334: 285-293. 10.1124/jpet.110.165498.PubMedCrossRef
60.
go back to reference Ji DB, Xu B, Liu JT, Ran FX, Cui JR: β-Escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells. Mol Carcinog. 2011, 50: 945-960. 10.1002/mc.20762.PubMedCrossRef Ji DB, Xu B, Liu JT, Ran FX, Cui JR: β-Escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells. Mol Carcinog. 2011, 50: 945-960. 10.1002/mc.20762.PubMedCrossRef
61.
go back to reference Shen D-Y, Kang J-H, Song W, Zhang W-Q, Li W-G, Zhao Y, Chen Q-X: Apoptosis of human cholangiocarcinoma cell lines induced by β-escin through mitochondrial caspase-dependent pathway. Phytother Res. 2011, 25: 1519-1526. 10.1002/ptr.3435.PubMedCrossRef Shen D-Y, Kang J-H, Song W, Zhang W-Q, Li W-G, Zhao Y, Chen Q-X: Apoptosis of human cholangiocarcinoma cell lines induced by β-escin through mitochondrial caspase-dependent pathway. Phytother Res. 2011, 25: 1519-1526. 10.1002/ptr.3435.PubMedCrossRef
62.
go back to reference Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O’Flaherty JD, Fennell DA, Richard D, O’Leary JJ, O’Byrne KJ: Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One. 2013, 8: e54193-10.1371/journal.pone.0054193.PubMedCentralPubMedCrossRef Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O’Flaherty JD, Fennell DA, Richard D, O’Leary JJ, O’Byrne KJ: Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One. 2013, 8: e54193-10.1371/journal.pone.0054193.PubMedCentralPubMedCrossRef
63.
go back to reference Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65: 6934-6942. 10.1158/0008-5472.CAN-04-4604.PubMedCrossRef Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65: 6934-6942. 10.1158/0008-5472.CAN-04-4604.PubMedCrossRef
64.
go back to reference Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK: Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol. 2003, 1: 66-10.1186/1477-7827-1-66.PubMedCentralPubMedCrossRef Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK: Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol. 2003, 1: 66-10.1186/1477-7827-1-66.PubMedCentralPubMedCrossRef
65.
go back to reference Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J, Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, Testa JR, Tasaka K, Murata Y: Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res. 2004, 10: 7645-7654. 10.1158/1078-0432.CCR-04-0958.PubMedCrossRef Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J, Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, Testa JR, Tasaka K, Murata Y: Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res. 2004, 10: 7645-7654. 10.1158/1078-0432.CCR-04-0958.PubMedCrossRef
66.
go back to reference Nakanishi C, Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005, 5: 297-309. 10.1038/nrc1588.PubMedCrossRef Nakanishi C, Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005, 5: 297-309. 10.1038/nrc1588.PubMedCrossRef
67.
go back to reference Kim S-H, Juhnn Y-S, Song Y-S: Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci. 2007, 1095: 82-89. 10.1196/annals.1397.012.PubMedCrossRef Kim S-H, Juhnn Y-S, Song Y-S: Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci. 2007, 1095: 82-89. 10.1196/annals.1397.012.PubMedCrossRef
68.
go back to reference Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005, 11: 7490-7498. 10.1158/1078-0432.CCR-05-1192.PubMedCrossRef Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005, 11: 7490-7498. 10.1158/1078-0432.CCR-05-1192.PubMedCrossRef
69.
go back to reference Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D’Alessandro N: Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett. 2005, 224: 53-65. 10.1016/j.canlet.2004.10.051.PubMedCrossRef Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D’Alessandro N: Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett. 2005, 224: 53-65. 10.1016/j.canlet.2004.10.051.PubMedCrossRef
70.
go back to reference Li M, Zhang Z, Hill DL, Wang H, Zhang R: Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 2007, 67: 1988-1996. 10.1158/0008-5472.CAN-06-3066.PubMedCrossRef Li M, Zhang Z, Hill DL, Wang H, Zhang R: Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 2007, 67: 1988-1996. 10.1158/0008-5472.CAN-06-3066.PubMedCrossRef
71.
go back to reference Zambonin L, Caliceti C, Vieceli Dalla Sega F, Fiorentini D, Hrelia S, Landi L, Prata C: Dietary phenolic acids act as effective antioxidants in membrane models and in cultured cells, exhibiting proapoptotic effects in leukaemia cells. Oxid Med Cell Longev. 2012, 2012: 839298-PubMedCentralPubMedCrossRef Zambonin L, Caliceti C, Vieceli Dalla Sega F, Fiorentini D, Hrelia S, Landi L, Prata C: Dietary phenolic acids act as effective antioxidants in membrane models and in cultured cells, exhibiting proapoptotic effects in leukaemia cells. Oxid Med Cell Longev. 2012, 2012: 839298-PubMedCentralPubMedCrossRef
72.
go back to reference Niero ELDO, Machado-Santelli GM: Cinnamic acid induces apoptotic cell death and cytoskeleton disruption in human melanoma cells. J Exp Clin Cancer Res. 2013, 32: 31-10.1186/1756-9966-32-31.PubMedCentralPubMedCrossRef Niero ELDO, Machado-Santelli GM: Cinnamic acid induces apoptotic cell death and cytoskeleton disruption in human melanoma cells. J Exp Clin Cancer Res. 2013, 32: 31-10.1186/1756-9966-32-31.PubMedCentralPubMedCrossRef
73.
go back to reference Tomizawa A, Kanno S, Osanai Y, Goto A, Sato C, Yomogida S, Ishikawa M: Induction of apoptosis by a potent caffeic acid derivative, caffeic acid undecyl ester, is mediated by mitochondrial damage in NALM-6 human B cell leukemia cells. Oncol Rep. 2013, 29: 425-429.PubMedCentralPubMed Tomizawa A, Kanno S, Osanai Y, Goto A, Sato C, Yomogida S, Ishikawa M: Induction of apoptosis by a potent caffeic acid derivative, caffeic acid undecyl ester, is mediated by mitochondrial damage in NALM-6 human B cell leukemia cells. Oncol Rep. 2013, 29: 425-429.PubMedCentralPubMed
74.
go back to reference Yang Y-I, Lee K-T, Park H-J, Kim TJ, Choi YS, Shih I-M, Choi J-H: Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway. Carcinogenesis. 2012, 33: 2488-2498. 10.1093/carcin/bgs302.PubMedCrossRef Yang Y-I, Lee K-T, Park H-J, Kim TJ, Choi YS, Shih I-M, Choi J-H: Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway. Carcinogenesis. 2012, 33: 2488-2498. 10.1093/carcin/bgs302.PubMedCrossRef
75.
go back to reference Arafa E-SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, Wani AA: Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 2009, 69: 8910-8917. 10.1158/0008-5472.CAN-09-1543.PubMedCentralCrossRef Arafa E-SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, Wani AA: Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 2009, 69: 8910-8917. 10.1158/0008-5472.CAN-09-1543.PubMedCentralCrossRef
76.
go back to reference Datta S, Brunet A, Greenberg M: Cellular survival: a play in three Akts. Genes Dev. 1999, 13: 2905-2927. 10.1101/gad.13.22.2905.PubMedCrossRef Datta S, Brunet A, Greenberg M: Cellular survival: a play in three Akts. Genes Dev. 1999, 13: 2905-2927. 10.1101/gad.13.22.2905.PubMedCrossRef
77.
go back to reference Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV, Cheng JQ: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000, 19: 2324-2330. 10.1038/sj.onc.1203598.PubMedCrossRef Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV, Cheng JQ: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000, 19: 2324-2330. 10.1038/sj.onc.1203598.PubMedCrossRef
78.
go back to reference Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ: AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001, 159: 431-437. 10.1016/S0002-9440(10)61714-2.PubMedCentralPubMedCrossRef Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ: AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001, 159: 431-437. 10.1016/S0002-9440(10)61714-2.PubMedCentralPubMedCrossRef
79.
go back to reference Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ: Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 2001, 61: 5985-5991.PubMed Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ: Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 2001, 61: 5985-5991.PubMed
80.
go back to reference Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009, 69: 3256-3261. 10.1158/0008-5472.CAN-08-4055.PubMedCentralPubMedCrossRef Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009, 69: 3256-3261. 10.1158/0008-5472.CAN-08-4055.PubMedCentralPubMedCrossRef
81.
go back to reference O’Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O’Donovan N, Slamon DJ: Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther. 2010, 9: 1489-1502. 10.1158/1535-7163.MCT-09-1171.PubMedCrossRef O’Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O’Donovan N, Slamon DJ: Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther. 2010, 9: 1489-1502. 10.1158/1535-7163.MCT-09-1171.PubMedCrossRef
82.
go back to reference Chen K-F, Chen H-L, Tai W-T, Feng W-C, Hsu C-H, Chen P-J, Cheng A-L: Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011, 337: 155-161. 10.1124/jpet.110.175786.PubMedCrossRef Chen K-F, Chen H-L, Tai W-T, Feng W-C, Hsu C-H, Chen P-J, Cheng A-L: Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011, 337: 155-161. 10.1124/jpet.110.175786.PubMedCrossRef
83.
go back to reference Lin F-C, Liu Y-P, Lai C-H, Shan Y-S, Cheng H-C, Hsu P-I, Lee C-H, Lee Y-C, Wang H-Y, Wang C-H, Cheng JQ, Hsiao M, Lu P-J: RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. Oncogene. 2012, 31: 4302-4316. 10.1038/onc.2011.596.PubMedCrossRef Lin F-C, Liu Y-P, Lai C-H, Shan Y-S, Cheng H-C, Hsu P-I, Lee C-H, Lee Y-C, Wang H-Y, Wang C-H, Cheng JQ, Hsiao M, Lu P-J: RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. Oncogene. 2012, 31: 4302-4316. 10.1038/onc.2011.596.PubMedCrossRef
84.
go back to reference Zheng Y, Wang R, Song H-Z, Pan B-Z, Zhang Y-W, Chen L-B: Epigenetic downregulation of RUNX3 by DNA methylation induces docetaxel chemoresistance in human lung adenocarcinoma cells by activation of the AKT pathway. Int J Biochem Cell Biol. 2013, 45: 1-10. 10.1016/j.biocel.2012.10.008.CrossRef Zheng Y, Wang R, Song H-Z, Pan B-Z, Zhang Y-W, Chen L-B: Epigenetic downregulation of RUNX3 by DNA methylation induces docetaxel chemoresistance in human lung adenocarcinoma cells by activation of the AKT pathway. Int J Biochem Cell Biol. 2013, 45: 1-10. 10.1016/j.biocel.2012.10.008.CrossRef
85.
go back to reference Liu B-N, Yan H-Q, Wu X, Pan Z-H, Zhu Y, Meng Z-W, Zhou Q-H, Xu K: Apoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen species. Cell Biochem Biophys. 2013, 66: 81-92. 10.1007/s12013-012-9456-9.PubMedCrossRef Liu B-N, Yan H-Q, Wu X, Pan Z-H, Zhu Y, Meng Z-W, Zhou Q-H, Xu K: Apoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen species. Cell Biochem Biophys. 2013, 66: 81-92. 10.1007/s12013-012-9456-9.PubMedCrossRef
86.
go back to reference Gao A-M, Ke Z-P, Wang J-N, Yang J-Y, Chen S-Y, Chen H: Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis. 2013, 34: 1806-1814. 10.1093/carcin/bgt108.PubMedCrossRef Gao A-M, Ke Z-P, Wang J-N, Yang J-Y, Chen S-Y, Chen H: Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis. 2013, 34: 1806-1814. 10.1093/carcin/bgt108.PubMedCrossRef
87.
go back to reference Frisch SM, Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994, 124: 619-626. 10.1083/jcb.124.4.619.PubMedCrossRef Frisch SM, Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994, 124: 619-626. 10.1083/jcb.124.4.619.PubMedCrossRef
88.
go back to reference Stoker M, O’Neill C, Berryman S, Waxman V: Anchorage and growth regulation in normal and virus-transformed cells. Int J Cancer. 1968, 3: 683-693. 10.1002/ijc.2910030517.PubMedCrossRef Stoker M, O’Neill C, Berryman S, Waxman V: Anchorage and growth regulation in normal and virus-transformed cells. Int J Cancer. 1968, 3: 683-693. 10.1002/ijc.2910030517.PubMedCrossRef
89.
go back to reference Liotta LA, Kohn E: Anoikis: cancer and the homeless cell. Nature. 2004, 430: 973-974. 10.1038/430973a.PubMedCrossRef Liotta LA, Kohn E: Anoikis: cancer and the homeless cell. Nature. 2004, 430: 973-974. 10.1038/430973a.PubMedCrossRef
90.
go back to reference Frisch SM, Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol. 2001, 13: 555-562. 10.1016/S0955-0674(00)00251-9.PubMedCrossRef Frisch SM, Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol. 2001, 13: 555-562. 10.1016/S0955-0674(00)00251-9.PubMedCrossRef
91.
go back to reference Martin SS, Leder P: Human MCF10A mammary epithelial cells undergo apoptosis following actin depolymerization that is independent of attachment and rescued by Bcl-2. Mol Cell Biol. 2001, 21: 6529-6536. 10.1128/MCB.21.19.6529-6536.2001.PubMedCentralPubMedCrossRef Martin SS, Leder P: Human MCF10A mammary epithelial cells undergo apoptosis following actin depolymerization that is independent of attachment and rescued by Bcl-2. Mol Cell Biol. 2001, 21: 6529-6536. 10.1128/MCB.21.19.6529-6536.2001.PubMedCentralPubMedCrossRef
92.
go back to reference Schmidt M, Hövelmann S, Beckers TL, Ho S: A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis. Br J Cancer. 2002, 87: 924-932. 10.1038/sj.bjc.6600566.PubMedCentralPubMedCrossRef Schmidt M, Hövelmann S, Beckers TL, Ho S: A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis. Br J Cancer. 2002, 87: 924-932. 10.1038/sj.bjc.6600566.PubMedCentralPubMedCrossRef
93.
go back to reference Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE: A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res. 2004, 64: 3987-3993. 10.1158/0008-5472.CAN-04-0424.PubMedCrossRef Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE: A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res. 2004, 64: 3987-3993. 10.1158/0008-5472.CAN-04-0424.PubMedCrossRef
94.
go back to reference Díaz-Montero CM, McIntyre BW: Acquisition of anoikis resistance in human osteosarcoma cells does not alter sensitivity to chemotherapeutic agents. BMC Cancer. 2005, 5: 39-10.1186/1471-2407-5-39.PubMedCentralPubMedCrossRef Díaz-Montero CM, McIntyre BW: Acquisition of anoikis resistance in human osteosarcoma cells does not alter sensitivity to chemotherapeutic agents. BMC Cancer. 2005, 5: 39-10.1186/1471-2407-5-39.PubMedCentralPubMedCrossRef
95.
go back to reference Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK: Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther. 2012, 11: 2556-2565. 10.1158/1535-7163.MCT-12-0463.PubMedCentralPubMedCrossRef Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK: Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther. 2012, 11: 2556-2565. 10.1158/1535-7163.MCT-12-0463.PubMedCentralPubMedCrossRef
96.
go back to reference Lindquist S, Craig EA: The heat-shock proteins. Annu Rev Genet. 1988, 22: 631-677. 10.1146/annurev.ge.22.120188.003215.PubMedCrossRef Lindquist S, Craig EA: The heat-shock proteins. Annu Rev Genet. 1988, 22: 631-677. 10.1146/annurev.ge.22.120188.003215.PubMedCrossRef
97.
go back to reference Frydman J, Nimmesgern E, Ohtsuka K, Hartl FU: Folding of nascent polypeptide chains in a high molecular mass assembly with molecular chaperones. Nature. 1994, 370: 111-117. 10.1038/370111a0.PubMedCrossRef Frydman J, Nimmesgern E, Ohtsuka K, Hartl FU: Folding of nascent polypeptide chains in a high molecular mass assembly with molecular chaperones. Nature. 1994, 370: 111-117. 10.1038/370111a0.PubMedCrossRef
98.
go back to reference Hernández MP, Chadli A, Toft DO: HSP40 binding is the first step in the HSP90 chaperoning pathway for the progesterone receptor. J Biol Chem. 2002, 277: 11873-11881. 10.1074/jbc.M111445200.PubMedCrossRef Hernández MP, Chadli A, Toft DO: HSP40 binding is the first step in the HSP90 chaperoning pathway for the progesterone receptor. J Biol Chem. 2002, 277: 11873-11881. 10.1074/jbc.M111445200.PubMedCrossRef
99.
go back to reference Jeong C-H, Park HB, Jang WJ, Jung SH, Seo YH: Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC). Bioorg Med Chem Lett. 2014, 24: 224-227. 10.1016/j.bmcl.2013.11.034.PubMedCrossRef Jeong C-H, Park HB, Jang WJ, Jung SH, Seo YH: Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC). Bioorg Med Chem Lett. 2014, 24: 224-227. 10.1016/j.bmcl.2013.11.034.PubMedCrossRef
100.
go back to reference Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez J-P, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA: Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013, 3: 430-443. 10.1158/2159-8290.CD-12-0440.PubMedCentralPubMedCrossRef Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez J-P, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA: Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013, 3: 430-443. 10.1158/2159-8290.CD-12-0440.PubMedCentralPubMedCrossRef
101.
go back to reference Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y: Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer. Cancer Sci. 2013, 104: 1346-1352. 10.1111/cas.12237.PubMedCrossRef Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y: Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer. Cancer Sci. 2013, 104: 1346-1352. 10.1111/cas.12237.PubMedCrossRef
102.
go back to reference Gallerne C, Prola A, Lemaire C: Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim Biophys Acta. 1833, 2013: 1356-1366. Gallerne C, Prola A, Lemaire C: Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim Biophys Acta. 1833, 2013: 1356-1366.
103.
go back to reference Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR: Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol. 2000, 2: 469-475. 10.1038/35019501.PubMedCrossRef Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR: Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol. 2000, 2: 469-475. 10.1038/35019501.PubMedCrossRef
104.
go back to reference Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES: Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol. 2000, 2: 476-483. 10.1038/35019510.PubMedCrossRef Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES: Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol. 2000, 2: 476-483. 10.1038/35019510.PubMedCrossRef
105.
go back to reference Grem JL, Morrison G, Guo X-D, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH: Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol. 2005, 23: 1885-1893. 10.1200/JCO.2005.12.085.PubMedCrossRef Grem JL, Morrison G, Guo X-D, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH: Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol. 2005, 23: 1885-1893. 10.1200/JCO.2005.12.085.PubMedCrossRef
106.
go back to reference Whetstone H, Lingwood C: 3′Sulfogalactolipid binding specifically inhibits Hsp70 ATPase activity in vitro. Biochemistry. 2003, 42: 1611-1617. 10.1021/bi026735t.PubMedCrossRef Whetstone H, Lingwood C: 3′Sulfogalactolipid binding specifically inhibits Hsp70 ATPase activity in vitro. Biochemistry. 2003, 42: 1611-1617. 10.1021/bi026735t.PubMedCrossRef
107.
go back to reference Rérole A-L, Gobbo J, De Thonel A, Schmitt E, Pais de Barros JP, Hammann A, Lanneau D, Fourmaux E, Deminov O, Micheau O, Lagrost L, Colas P, Kroemer G, Garrido C: Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res. 2011, 71: 484-495. 10.1158/0008-5472.CAN-10-1443.PubMedCrossRef Rérole A-L, Gobbo J, De Thonel A, Schmitt E, Pais de Barros JP, Hammann A, Lanneau D, Fourmaux E, Deminov O, Micheau O, Lagrost L, Colas P, Kroemer G, Garrido C: Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res. 2011, 71: 484-495. 10.1158/0008-5472.CAN-10-1443.PubMedCrossRef
108.
go back to reference Endo H, Yano M, Okumura Y, Kido H: Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. Cell Death Dis. 2014, 5: e1027-10.1038/cddis.2013.550.PubMedCentralPubMedCrossRef Endo H, Yano M, Okumura Y, Kido H: Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. Cell Death Dis. 2014, 5: e1027-10.1038/cddis.2013.550.PubMedCentralPubMedCrossRef
109.
go back to reference Sterrenberg JN, Blatch GL, Edkins AL: Human DNAJ in cancer and stem cells. Cancer Lett. 2011, 312: 129-142. 10.1016/j.canlet.2011.08.019.PubMedCrossRef Sterrenberg JN, Blatch GL, Edkins AL: Human DNAJ in cancer and stem cells. Cancer Lett. 2011, 312: 129-142. 10.1016/j.canlet.2011.08.019.PubMedCrossRef
110.
go back to reference Rane MJ, Pan Y, Singh S, Powell DW, Wu R, Cummins T, Chen Q, McLeish KR, Klein JB: Heat shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem. 2003, 278: 27828-27835. 10.1074/jbc.M303417200.PubMedCrossRef Rane MJ, Pan Y, Singh S, Powell DW, Wu R, Cummins T, Chen Q, McLeish KR, Klein JB: Heat shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem. 2003, 278: 27828-27835. 10.1074/jbc.M303417200.PubMedCrossRef
111.
go back to reference Qi S, Xin Y, Qi Z, Xu Y, Diao Y, Lan L, Luo L, Yin Z: HSP27 phosphorylation modulates TRAIL-induced activation of Src-Akt/ERK signaling through interaction with β-arrestin2. Cell Signal. 2014, 26: 594-602. 10.1016/j.cellsig.2013.11.033.PubMedCrossRef Qi S, Xin Y, Qi Z, Xu Y, Diao Y, Lan L, Luo L, Yin Z: HSP27 phosphorylation modulates TRAIL-induced activation of Src-Akt/ERK signaling through interaction with β-arrestin2. Cell Signal. 2014, 26: 594-602. 10.1016/j.cellsig.2013.11.033.PubMedCrossRef
112.
113.
go back to reference Hsu H-S, Lin J-H, Huang W-C, Hsu T-W, Su K, Chiou S-H, Tsai Y-T, Hung S-C: Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer. 2011, 117: 1516-1528. 10.1002/cncr.25599.PubMedCrossRef Hsu H-S, Lin J-H, Huang W-C, Hsu T-W, Su K, Chiou S-H, Tsai Y-T, Hung S-C: Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer. 2011, 117: 1516-1528. 10.1002/cncr.25599.PubMedCrossRef
114.
go back to reference McConnell JR, McAlpine SR: Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorg Med Chem Lett. 2013, 23: 1923-1928. 10.1016/j.bmcl.2013.02.014.PubMedCentralPubMedCrossRef McConnell JR, McAlpine SR: Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorg Med Chem Lett. 2013, 23: 1923-1928. 10.1016/j.bmcl.2013.02.014.PubMedCentralPubMedCrossRef
115.
go back to reference Prestwich GD: Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery. Acc Chem Res. 2008, 41: 139-148. 10.1021/ar7000827.PubMedCrossRef Prestwich GD: Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery. Acc Chem Res. 2008, 41: 139-148. 10.1021/ar7000827.PubMedCrossRef
116.
go back to reference Cukierman E, Pankov R, Stevens DR, Yamada KM: Taking cell-matrix adhesions to the third dimension. Science. 2001, 294: 1708-1712. 10.1126/science.1064829.PubMedCrossRef Cukierman E, Pankov R, Stevens DR, Yamada KM: Taking cell-matrix adhesions to the third dimension. Science. 2001, 294: 1708-1712. 10.1126/science.1064829.PubMedCrossRef
117.
go back to reference Bokhari M, Carnachan RJ, Cameron NR, Przyborski SA: Culture of HepG2 liver cells on three dimensional polystyrene scaffolds enhances cell structure and function during toxicological challenge. J Anat. 2007, 211: 567-576.PubMedCentralPubMed Bokhari M, Carnachan RJ, Cameron NR, Przyborski SA: Culture of HepG2 liver cells on three dimensional polystyrene scaffolds enhances cell structure and function during toxicological challenge. J Anat. 2007, 211: 567-576.PubMedCentralPubMed
118.
go back to reference Hall HG, Farson DA, Bissell MJ: Lumen formation by epithelial cell lines in response to collagen overlay: a morphogenetic model in culture. Proc Natl Acad Sci U S A. 1982, 79: 4672-4676. 10.1073/pnas.79.15.4672.PubMedCentralPubMedCrossRef Hall HG, Farson DA, Bissell MJ: Lumen formation by epithelial cell lines in response to collagen overlay: a morphogenetic model in culture. Proc Natl Acad Sci U S A. 1982, 79: 4672-4676. 10.1073/pnas.79.15.4672.PubMedCentralPubMedCrossRef
119.
go back to reference Do Amaral JB, Urabayashi MS, Machado-Santelli GM: Cell death and lumen formation in spheroids of MCF-7 cells. Cell Biol Int. 2010, 34: 267-274. 10.1042/CBI20090024.PubMedCrossRef Do Amaral JB, Urabayashi MS, Machado-Santelli GM: Cell death and lumen formation in spheroids of MCF-7 cells. Cell Biol Int. 2010, 34: 267-274. 10.1042/CBI20090024.PubMedCrossRef
120.
go back to reference Do Amaral JB, Rezende-Teixeira P, Freitas VM, Machado-Santelli GM: MCF-7 cells as a three-dimensional model for the study of human breast cancer. Tissue Eng Part C Methods. 2011, 17: 1097-1107. 10.1089/ten.tec.2011.0260.PubMedCrossRef Do Amaral JB, Rezende-Teixeira P, Freitas VM, Machado-Santelli GM: MCF-7 cells as a three-dimensional model for the study of human breast cancer. Tissue Eng Part C Methods. 2011, 17: 1097-1107. 10.1089/ten.tec.2011.0260.PubMedCrossRef
121.
go back to reference Page H, Flood P, Reynaud EG: Three-dimensional tissue cultures: current trends and beyond. Cell Tissue Res. 2013, 352: 123-131. 10.1007/s00441-012-1441-5.PubMedCrossRef Page H, Flood P, Reynaud EG: Three-dimensional tissue cultures: current trends and beyond. Cell Tissue Res. 2013, 352: 123-131. 10.1007/s00441-012-1441-5.PubMedCrossRef
122.
go back to reference Spencer VA, Xu R, Bissell MJ: Gene expression in the third dimension: the ECM-nucleus connection. J Mammary Gland Biol Neoplasia. 2010, 15: 65-71. 10.1007/s10911-010-9163-3.PubMedCentralPubMedCrossRef Spencer VA, Xu R, Bissell MJ: Gene expression in the third dimension: the ECM-nucleus connection. J Mammary Gland Biol Neoplasia. 2010, 15: 65-71. 10.1007/s10911-010-9163-3.PubMedCentralPubMedCrossRef
123.
go back to reference Luca AC, Mersch S, Deenen R, Schmidt S, Messner I, Schäfer K-L, Baldus SE, Huckenbeck W, Piekorz RP, Knoefel WT, Krieg A, Stoecklein NH: Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS One. 2013, 8: e59689-10.1371/journal.pone.0059689.PubMedCentralPubMedCrossRef Luca AC, Mersch S, Deenen R, Schmidt S, Messner I, Schäfer K-L, Baldus SE, Huckenbeck W, Piekorz RP, Knoefel WT, Krieg A, Stoecklein NH: Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS One. 2013, 8: e59689-10.1371/journal.pone.0059689.PubMedCentralPubMedCrossRef
124.
go back to reference Santini MT, Rainaldi G, Indovina PL: Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Crit Rev Oncol Hematol. 2000, 36: 75-87. 10.1016/S1040-8428(00)00078-0.PubMedCrossRef Santini MT, Rainaldi G, Indovina PL: Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Crit Rev Oncol Hematol. 2000, 36: 75-87. 10.1016/S1040-8428(00)00078-0.PubMedCrossRef
125.
go back to reference Waleh NS, Gallo J, Grant TD, Murphy BJ, Kramer RH, Sutherland RM: Selective down-regulation of integrin receptors in spheroids of squamous cell carcinoma. Cancer Res. 1994, 54: 838-843.PubMed Waleh NS, Gallo J, Grant TD, Murphy BJ, Kramer RH, Sutherland RM: Selective down-regulation of integrin receptors in spheroids of squamous cell carcinoma. Cancer Res. 1994, 54: 838-843.PubMed
126.
go back to reference Hauptmann S, Denkert C, Löhrke H, Tietze L, Ott S, Klosterhalfen B, Mittermayer C: Integrin expression on colorectal tumor cells growing as monolayers, as multicellular tumor spheroids, or in nude mice. Int J Cancer. 1995, 61: 819-825. 10.1002/ijc.2910610613.PubMedCrossRef Hauptmann S, Denkert C, Löhrke H, Tietze L, Ott S, Klosterhalfen B, Mittermayer C: Integrin expression on colorectal tumor cells growing as monolayers, as multicellular tumor spheroids, or in nude mice. Int J Cancer. 1995, 61: 819-825. 10.1002/ijc.2910610613.PubMedCrossRef
127.
go back to reference Friedrich J, Eder W, Castaneda J, Doss M, Huber E, Ebner R, Kunz-Schughart LA: A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay. J Biomol Screen. 2007, 12: 925-937. 10.1177/1087057107306839.PubMedCrossRef Friedrich J, Eder W, Castaneda J, Doss M, Huber E, Ebner R, Kunz-Schughart LA: A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay. J Biomol Screen. 2007, 12: 925-937. 10.1177/1087057107306839.PubMedCrossRef
128.
go back to reference Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA: Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 2010, 148: 3-15. 10.1016/j.jbiotec.2010.01.012.PubMedCrossRef Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA: Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 2010, 148: 3-15. 10.1016/j.jbiotec.2010.01.012.PubMedCrossRef
129.
go back to reference Fourré N, Millot J-M, Garnotel R, Jeannesson P: In situ analysis of doxorubicin uptake and cytotoxicity in a 3D culture model of human HT-1080 fibrosarcoma cells. Anticancer Res. 2006, 26: 4623-4626.PubMed Fourré N, Millot J-M, Garnotel R, Jeannesson P: In situ analysis of doxorubicin uptake and cytotoxicity in a 3D culture model of human HT-1080 fibrosarcoma cells. Anticancer Res. 2006, 26: 4623-4626.PubMed
130.
go back to reference Yip D, Cho CH: A multicellular 3D heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing. Biochem Biophys Res Commun. 2013, 433: 327-332. 10.1016/j.bbrc.2013.03.008.PubMedCrossRef Yip D, Cho CH: A multicellular 3D heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing. Biochem Biophys Res Commun. 2013, 433: 327-332. 10.1016/j.bbrc.2013.03.008.PubMedCrossRef
131.
go back to reference Millerot-Serrurot E, Guilbert M, Fourré N, Witkowski W, Said G, Van Gulick L, Terryn C, Zahm J-M, Garnotel R, Jeannesson P: 3D collagen type I matrix inhibits the antimigratory effect of doxorubicin. Cancer Cell Int. 2010, 10: 26-10.1186/1475-2867-10-26.PubMedCentralPubMedCrossRef Millerot-Serrurot E, Guilbert M, Fourré N, Witkowski W, Said G, Van Gulick L, Terryn C, Zahm J-M, Garnotel R, Jeannesson P: 3D collagen type I matrix inhibits the antimigratory effect of doxorubicin. Cancer Cell Int. 2010, 10: 26-10.1186/1475-2867-10-26.PubMedCentralPubMedCrossRef
132.
go back to reference Godugu C, Patel AR, Desai U, Andey T, Sams A, Singh M: AlgiMatrixTM based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One. 2013, 8: e53708-10.1371/journal.pone.0053708.PubMedCentralPubMedCrossRef Godugu C, Patel AR, Desai U, Andey T, Sams A, Singh M: AlgiMatrixTM based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One. 2013, 8: e53708-10.1371/journal.pone.0053708.PubMedCentralPubMedCrossRef
133.
go back to reference Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999, 93: 1658-1667.PubMed Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999, 93: 1658-1667.PubMed
134.
go back to reference Sanz-Rodríguez F, Teixidó J: VLA-4-dependent myeloma cell adhesion. Leuk Lymphoma. 2001, 41: 239-245. 10.3109/10428190109057979.PubMedCrossRef Sanz-Rodríguez F, Teixidó J: VLA-4-dependent myeloma cell adhesion. Leuk Lymphoma. 2001, 41: 239-245. 10.3109/10428190109057979.PubMedCrossRef
135.
go back to reference Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JCR, Giancotti F, Werb Z, Bissell MJ: Beta4 Integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell. 2002, 2: 205-216. 10.1016/S1535-6108(02)00125-3.PubMedCentralPubMedCrossRef Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JCR, Giancotti F, Werb Z, Bissell MJ: Beta4 Integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell. 2002, 2: 205-216. 10.1016/S1535-6108(02)00125-3.PubMedCentralPubMedCrossRef
136.
go back to reference Schmidmaier R, Baumann P: ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr Med Chem. 2008, 15: 978-990. 10.2174/092986708784049667.PubMedCrossRef Schmidmaier R, Baumann P: ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr Med Chem. 2008, 15: 978-990. 10.2174/092986708784049667.PubMedCrossRef
137.
go back to reference Westhoff M-A, Fulda S: Adhesion-mediated apoptosis resistance in cancer. Drug Resist Updat. 2009, 12: 127-136. 10.1016/j.drup.2009.08.001.PubMedCrossRef Westhoff M-A, Fulda S: Adhesion-mediated apoptosis resistance in cancer. Drug Resist Updat. 2009, 12: 127-136. 10.1016/j.drup.2009.08.001.PubMedCrossRef
138.
go back to reference Longati P, Jia X, Eimer J, Wagman A, Witt M-R, Rehnmark S, Verbeke C, Toftgård R, Löhr M, Heuchel RL: 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer. 2013, 13: 95-10.1186/1471-2407-13-95.PubMedCentralPubMedCrossRef Longati P, Jia X, Eimer J, Wagman A, Witt M-R, Rehnmark S, Verbeke C, Toftgård R, Löhr M, Heuchel RL: 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer. 2013, 13: 95-10.1186/1471-2407-13-95.PubMedCentralPubMedCrossRef
139.
go back to reference Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC: Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials. 2010, 31: 8494-8506. 10.1016/j.biomaterials.2010.07.064.PubMedCrossRef Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC: Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials. 2010, 31: 8494-8506. 10.1016/j.biomaterials.2010.07.064.PubMedCrossRef
140.
go back to reference Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, McGuckin MA, Harris JM, Clements JA: Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. PLoS One. 2013, 8: e57056-10.1371/journal.pone.0057056.PubMedCentralPubMedCrossRef Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, McGuckin MA, Harris JM, Clements JA: Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. PLoS One. 2013, 8: e57056-10.1371/journal.pone.0057056.PubMedCentralPubMedCrossRef
141.
go back to reference Chen J, Wang J, Chen D, Yang J, Yang C, Zhang Y, Zhang H, Dou J: Evaluation of characteristics of CD44 + CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biol. 2013, 14: 7-10.1186/1471-2121-14-7.PubMedCentralPubMedCrossRef Chen J, Wang J, Chen D, Yang J, Yang C, Zhang Y, Zhang H, Dou J: Evaluation of characteristics of CD44 + CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biol. 2013, 14: 7-10.1186/1471-2121-14-7.PubMedCentralPubMedCrossRef
142.
go back to reference Yang T-M, Barbone D, Fennell DA, Broaddus VC: Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol. 2009, 41: 14-23. 10.1165/rcmb.2008-0320OC.PubMedCentralPubMedCrossRef Yang T-M, Barbone D, Fennell DA, Broaddus VC: Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol. 2009, 41: 14-23. 10.1165/rcmb.2008-0320OC.PubMedCentralPubMedCrossRef
143.
go back to reference Lee SY, Jeong E, Jeon HM, Kim CH, Kang HS: Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids. Oncol Rep. 2010, 24: 73-79.PubMed Lee SY, Jeong E, Jeon HM, Kim CH, Kang HS: Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids. Oncol Rep. 2010, 24: 73-79.PubMed
144.
go back to reference Nirmalanandhan VS, Duren A, Hendricks P, Vielhauer G, Sittampalam GS: Activity of anticancer agents in a three-dimensional cell culture model. Assay Drug Dev Technol. 2010, 8: 581-590. 10.1089/adt.2010.0276.PubMedCrossRef Nirmalanandhan VS, Duren A, Hendricks P, Vielhauer G, Sittampalam GS: Activity of anticancer agents in a three-dimensional cell culture model. Assay Drug Dev Technol. 2010, 8: 581-590. 10.1089/adt.2010.0276.PubMedCrossRef
145.
go back to reference Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ: Tumour-initiating cells vs. cancer “stem” cells and CD133: what’s in the name?. Biochem Biophys Res Commun. 2007, 355: 855-859. 10.1016/j.bbrc.2007.01.159.PubMedCrossRef Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ: Tumour-initiating cells vs. cancer “stem” cells and CD133: what’s in the name?. Biochem Biophys Res Commun. 2007, 355: 855-859. 10.1016/j.bbrc.2007.01.159.PubMedCrossRef
146.
go back to reference Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 2005, 5: 275-284. 10.1038/nrc1590.PubMedCrossRef Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 2005, 5: 275-284. 10.1038/nrc1590.PubMedCrossRef
147.
go back to reference Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008, 8: 755-768. 10.1038/nrc2499.PubMedCrossRef Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008, 8: 755-768. 10.1038/nrc2499.PubMedCrossRef
148.
go back to reference Takaishi S, Okumura T, Tu S, Wang SSW, Shibata W, Vigneshwaran R, Gordon SAK, Shimada Y, Wang TC: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009, 27: 1006-1020. 10.1002/stem.30.PubMedCentralPubMedCrossRef Takaishi S, Okumura T, Tu S, Wang SSW, Shibata W, Vigneshwaran R, Gordon SAK, Shimada Y, Wang TC: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009, 27: 1006-1020. 10.1002/stem.30.PubMedCentralPubMedCrossRef
149.
go back to reference Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G: The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg. 2009, 36: 446-453. 10.1016/j.ejcts.2009.03.063.PubMedCrossRef Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G: The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg. 2009, 36: 446-453. 10.1016/j.ejcts.2009.03.063.PubMedCrossRef
150.
go back to reference Awad O, Yustein JT, Shah P, Gul N, Katuri V, Neill AO, Kong Y, Brown ML, Toretsky JA, Loeb DM, O’Neill A: High ALDH activity identifies chemotherapy-resistant Ewing’s sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One. 2010, 5: e13943-10.1371/journal.pone.0013943.PubMedCentralPubMedCrossRef Awad O, Yustein JT, Shah P, Gul N, Katuri V, Neill AO, Kong Y, Brown ML, Toretsky JA, Loeb DM, O’Neill A: High ALDH activity identifies chemotherapy-resistant Ewing’s sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One. 2010, 5: e13943-10.1371/journal.pone.0013943.PubMedCentralPubMedCrossRef
151.
go back to reference Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S, Miotti S, Tosello V, Zamarchi R, Corradin A, Minuzzo S, Rossi E, Basso G, Amadori A: The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res. 2008, 68: 5658-5668. 10.1158/0008-5472.CAN-07-6341.PubMedCrossRef Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S, Miotti S, Tosello V, Zamarchi R, Corradin A, Minuzzo S, Rossi E, Basso G, Amadori A: The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res. 2008, 68: 5658-5668. 10.1158/0008-5472.CAN-07-6341.PubMedCrossRef
152.
go back to reference Rybak AP, He L, Kapoor A, Cutz J-C, Tang D: Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim Biophys Acta. 1813, 2011: 683-694. Rybak AP, He L, Kapoor A, Cutz J-C, Tang D: Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim Biophys Acta. 1813, 2011: 683-694.
153.
go back to reference Pastrana E, Silva-Vargas V, Doetsch F: Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011, 8: 486-498. 10.1016/j.stem.2011.04.007.PubMedCentralPubMedCrossRef Pastrana E, Silva-Vargas V, Doetsch F: Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011, 8: 486-498. 10.1016/j.stem.2011.04.007.PubMedCentralPubMedCrossRef
154.
go back to reference Marhaba R, Zöller M: CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004, 35: 211-231.PubMedCrossRef Marhaba R, Zöller M: CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004, 35: 211-231.PubMedCrossRef
155.
go back to reference Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007, 104: 973-978. 10.1073/pnas.0610117104.PubMedCentralPubMedCrossRef Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007, 104: 973-978. 10.1073/pnas.0610117104.PubMedCentralPubMedCrossRef
156.
go back to reference Marchitti SA, Brocker C, Stagos D, Vasiliou V: Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol. 2008, 4: 697-720. 10.1517/17425255.4.6.697.PubMedCentralPubMedCrossRef Marchitti SA, Brocker C, Stagos D, Vasiliou V: Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol. 2008, 4: 697-720. 10.1517/17425255.4.6.697.PubMedCentralPubMedCrossRef
157.
go back to reference Magni M, Shammah S, Schiró R, Mellado W, Dalla-Favera R, Gianni AM: Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood. 1996, 87: 1097-1103.PubMed Magni M, Shammah S, Schiró R, Mellado W, Dalla-Favera R, Gianni AM: Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood. 1996, 87: 1097-1103.PubMed
158.
go back to reference Sládek NE, Kollander R, Sreerama L, Kiang DT: Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol. 2002, 49: 309-321. 10.1007/s00280-001-0412-4.PubMedCrossRef Sládek NE, Kollander R, Sreerama L, Kiang DT: Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol. 2002, 49: 309-321. 10.1007/s00280-001-0412-4.PubMedCrossRef
159.
go back to reference Cheung AMS, Wan TSK, Leung JCK, Chan LYY, Huang H, Kwong YL, Liang R, Leung AYH: Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia. 2007, 21: 1423-1430. 10.1038/sj.leu.2404721.PubMedCrossRef Cheung AMS, Wan TSK, Leung JCK, Chan LYY, Huang H, Kwong YL, Liang R, Leung AYH: Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia. 2007, 21: 1423-1430. 10.1038/sj.leu.2404721.PubMedCrossRef
160.
go back to reference Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1: 555-567. 10.1016/j.stem.2007.08.014.PubMedCentralPubMedCrossRef Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1: 555-567. 10.1016/j.stem.2007.08.014.PubMedCentralPubMedCrossRef
161.
go back to reference Marcato P, Dean CA, Giacomantonio CA, Lee PWK: Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle. 2011, 10: 1378-1384. 10.4161/cc.10.9.15486.PubMedCrossRef Marcato P, Dean CA, Giacomantonio CA, Lee PWK: Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle. 2011, 10: 1378-1384. 10.4161/cc.10.9.15486.PubMedCrossRef
162.
go back to reference Ionta M, Rosa MCC, Almeida RBB, Freitas VMM, Rezende-Teixeira P, Machado-Santelli GMM: Retinoic acid and cAMP inhibit rat hepatocellular carcinoma cell proliferation and enhance cell differentiation. Braz J Med Biol Res. 2012, 45: 721-729. 10.1590/S0100-879X2012007500087.PubMedCentralPubMedCrossRef Ionta M, Rosa MCC, Almeida RBB, Freitas VMM, Rezende-Teixeira P, Machado-Santelli GMM: Retinoic acid and cAMP inhibit rat hepatocellular carcinoma cell proliferation and enhance cell differentiation. Braz J Med Biol Res. 2012, 45: 721-729. 10.1590/S0100-879X2012007500087.PubMedCentralPubMedCrossRef
163.
go back to reference Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996, 183: 1797-1806. 10.1084/jem.183.4.1797.PubMedCrossRef Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996, 183: 1797-1806. 10.1084/jem.183.4.1797.PubMedCrossRef
164.
go back to reference Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G: Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 2013, 27: 13-24. 10.1096/fj.12-218222.PubMedCrossRef Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G: Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 2013, 27: 13-24. 10.1096/fj.12-218222.PubMedCrossRef
165.
go back to reference Lee H, Park S, Kim JB, Kim J, Kim H: Entrapped doxorubicin nanoparticles for the treatment of metastatic anoikis-resistant cancer cells. Cancer Lett. 2013, 332: 110-119. 10.1016/j.canlet.2013.01.021.PubMedCrossRef Lee H, Park S, Kim JB, Kim J, Kim H: Entrapped doxorubicin nanoparticles for the treatment of metastatic anoikis-resistant cancer cells. Cancer Lett. 2013, 332: 110-119. 10.1016/j.canlet.2013.01.021.PubMedCrossRef
166.
go back to reference Reynolds BA, Weiss S: Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science. 1992, 255: 1707-1710. 10.1126/science.1553558.PubMedCrossRef Reynolds BA, Weiss S: Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science. 1992, 255: 1707-1710. 10.1126/science.1553558.PubMedCrossRef
167.
go back to reference Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN: Cancer stem cells in lung cancer: evidence and controversies. Respirology. 2013, 18: 757-764. 10.1111/resp.12094.PubMedCentralPubMedCrossRef Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN: Cancer stem cells in lung cancer: evidence and controversies. Respirology. 2013, 18: 757-764. 10.1111/resp.12094.PubMedCentralPubMedCrossRef
Metadata
Title
The multiple facets of drug resistance: one history, different approaches
Authors
Evandro Luís Niero
Bianca Rocha-Sales
Camila Lauand
Beatriz Araujo Cortez
Marcelo Medina de Souza
Paula Rezende-Teixeira
Marcel Shiniti Urabayashi
Adam Arai Martens
Jorge Henrique Neves
Gláucia Maria Machado-Santelli
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-33-37

Other articles of this Issue 1/2014

Journal of Experimental & Clinical Cancer Research 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine